UB Paderborn / Katalog / Suche / in CDI

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery

Journal of thrombosis and haemostasis, 2019-01, Vol.17 (1), p.52-62

2019

Link zum Volltext

Verfügbarkeit prüfen

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-03, Vol.23 (2), p.238-246

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.65-72

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy and pharmacokinetics of rVIII‐SingleChain in children with severe hemophilia A: results of a multicenter clinical trial

Journal of thrombosis and haemostasis, 2017-04, Vol.15 (4), p.636-644

2017

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-09, Vol.20 (5), p.644-650

2014

Link zum Volltext

Verfügbarkeit prüfen

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S458-S459

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.15-24

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-09, Vol.20 (5), p.651-658

2014

Link zum Volltext

Verfügbarkeit prüfen

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-09, Vol.20 (5), p.674-681

2014

Link zum Volltext

Verfügbarkeit prüfen

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-03, Vol.21 (2), p.196-203

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

The New England journal of medicine, 2023-08, Vol.389 (9), p.783-794

2023

Link zum Volltext

Verfügbarkeit prüfen

PB1842 ROLE OF THROMBOELASTOGRAPHY IN THE MONITORING OF PROPHYLACTIC TREATMENT IN PATIENTS WITH SEVERE HAEMOPHILIA A

HemaSphere, 2019-06, Vol.3 (S1), p.842-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

Journal of blood medicine, 2020-01, Vol.11, p.345-356

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)

Journal of blood medicine, 2021-01, Vol.12, p.483-495

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

Journal of blood medicine, 2020-01, Vol.11, p.213-225

2020

Link zum Volltext

Verfügbarkeit prüfen

The Ways of Improving the Psychophysiological Selection and Monitoring of Professionally Important Qualities of Operators

Ukraïnsʹkij žurnal medicini, bìologìï ta sportu, 2017-05, Vol.2 (2), p.149-160

2017

Link zum Volltext

Verfügbarkeit prüfen

CORRELATION OF THE PARAMETERS OF THROMBO-ELASTOGRAM WITH THE RESULTS OF COAGULATIOIN TESTS IN HAEMOPHILIA A PATIENTS DURING PROPHYLAXIS

Eastern Ukrainian medical journal, 2019-09, Vol.7 (3), p.215-225

Krasivska, V. V.

2019

Link zum Volltext

Verfügbarkeit prüfen

The international factor IX treatment network survey

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-05, Vol.18 (3), p.e60-e62

2012

Link zum Volltext

Verfügbarkeit prüfen

USE OF A HIGH PURITY FACTOR IX (FIX) CONCENTRATE IN SURGERY

Journal of thrombosis and haemostasis, 2007-07, Vol.5, p.P-M-159-P-M-159

2007

Link zum Volltext

Verfügbarkeit prüfen

Characterization of immune disorders in hemophiliac patients with the identification of inhibitor-dependence in replacement transfusion therapy

Likars'ka sprava, 2001-05 (3), p.39

2001

Link zum Volltext

Verfügbarkeit prüfen

Mesenteric thrombosis in patients with coronavirus disease: comprehensive assessment and treatment

Medychni perspektyvy, 2022-01, Vol.27 (1), p.86-91

2022

Link zum Volltext

Verfügbarkeit prüfen

Pretreatment Influence on Titanium Surface Properties After Gas Nitriding

Journal of materials engineering and performance, 2017-10, Vol.26 (10), p.5072-5078

2017

Link zum Volltext

Verfügbarkeit prüfen

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

Journal of antimicrobial chemotherapy, 2010-11, Vol.65 (suppl-4), p.iv53-iv65

2010

Link zum Volltext

Verfügbarkeit prüfen

Influence of Thermochemical Treatment on the Surface Topography of Titanium

Metallofizika i noveĭshie tekhnologii, 2017-12, Vol.39 (9), p.1183-1196

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Safety, efficacy and pharmacokinetics of rVIII‐SingleChain in children with severe hemophilia A: results of a multicenter clinical trial

Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study

TREATMENT BURDEN AND PATIENT PREFERENCE IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS ON CONCIZUMAB PROPHYLAXIS: RESULTS FROM THE PHASE 3 EXPLORER7 STUDY

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study

Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326)

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

PB1842 ROLE OF THROMBOELASTOGRAPHY IN THE MONITORING OF PROPHYLACTIC TREATMENT IN PATIENTS WITH SEVERE HAEMOPHILIA A

An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study)

Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)

Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

The Ways of Improving the Psychophysiological Selection and Monitoring of Professionally Important Qualities of Operators

CORRELATION OF THE PARAMETERS OF THROMBO-ELASTOGRAM WITH THE RESULTS OF COAGULATIOIN TESTS IN HAEMOPHILIA A PATIENTS DURING PROPHYLAXIS

The international factor IX treatment network survey

USE OF A HIGH PURITY FACTOR IX (FIX) CONCENTRATE IN SURGERY

Characterization of immune disorders in hemophiliac patients with the identification of inhibitor-dependence in replacement transfusion therapy

Mesenteric thrombosis in patients with coronavirus disease: comprehensive assessment and treatment

Pretreatment Influence on Titanium Surface Properties After Gas Nitriding

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

Influence of Thermochemical Treatment on the Surface Topography of Titanium

Suchergebnisse filtern